
Ventyx Biosciences Investor Relations Material
Latest events

Q1 2024
Ventyx Biosciences

Q1 2025
8 May, 2025

Q4 2024
27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Ventyx Biosciences Inc
Access all reports
Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel oral therapies designed to treat patients with autoimmune and inflammatory disorders. The company's approach involves selectively modulating key immune targets to create differentiated medicines. Ventyx Biosciences is working on several promising drug candidates, including a selective allosteric tyrosine kinase type 2 inhibitor and a sphingosine 1 phosphate receptor modulator, which are in various stages of clinical trials targeting conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Additionally, they are developing inhibitors targeting the NLRP3 inflammasome. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
VTYX
Country
🇺🇸 United States